Article Sidebar

Submitted
10 January 2021
Accepted
11 January 2021
Published
30 June 2019
Download
PDF
Statistic
Read Counter : 2913 Download : 1338

Main Article Content

Abstract

Anemia in patient with chronic kidney disease could cause a lot of complication. The first line therapy of this condition is by treating with erythropoiesis-stimulating agents (ESA) or called erythropoietin. The erythropoietin alpha and beta were two types of the human recombinant erythropoietin that are usually used in Indonesia. The aim of this study was to determine the effectivity of erythropoietin alpha compared to erythropoietin beta especially in haemoglobin and haematocrit level. This prospective observational study was conducted in March – September 2016. The inclusion criteria were CKD stage 5 patients with a minimum of 3 months of regular hemodialysis, Hb <10 g/dL with enough iron status ST > 20% and FS > 200ng/mL. The methology of this study had been approved by the Health Research Ethics Committee of the Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya. Patients received 2000 IU subcutaneous erythropoietin twice a week on both groups. Blood sample was withdrawn in pre-treatment and after 4 weeks of post erythropoietin therapy treatment for measurement of haemoglobin and haematocrit. Target for this erythropoietin therapy are increase of Hb 0.5 – 1.5 g/dL (not to exceed 12 g/dL) and increase of Hct level 2 – 4 % in 4 weeks. Based on the inclusion criteria, there were 20 patients in this study (10 patient each of both erythropoietin alpha either beta group) that consist of 7 women and 13 men. After the treatment, the mean of increased haemoglobin level for erythropoietin alpha group was 1.28 ± 0.80 g/dL (p=0.001) and erythropoietin beta was 0.37 ± 0.95 g/dL (p=0.254). The mean of increased haematocrit level for erytropoietin alpha group was 3.56 ± 3.46 % (p=0.010) and erythropoietin beta was 1.34 ± 2.71 % (p=0.152). In comparison of haemoglobin and haematocrit achievement in both groups showed that erythropoietin alpha gave better achievement in haemoglobin parameter (p=0.033), but there were no differences in both groups on haematocrit parameters (p=0.127).

Keywords

Eritropoetin alpha beta chronic kidney disease hemoglobin hematocrit ferritin ST hemodialysis

Article Details

License

Copyright (c) 2019 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Prasetya, A. A. N. P. R., Suprapti, B., & Shanti, B. D. (2019). Effectivity of Erythropoietin Alpha Compared to Erythropoietin Beta in Patients with Chronic Kidney Disease-Anemia on Hemodialysis. Folia Medica Indonesiana, 55(2), 82–88. https://doi.org/10.20473/fmi.v55i2.24461
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Cohan RA, Madadkar-Sobhani A, Khanahmad H, Roohvand F, Aghasadeghi MR, Hedayati MH, et al (2011). Design, modelling, expression, and chemo-selective PEGylation of a new nanosize cystein analog of erythropoietin. International Journal of Nanomedicine 6, 1217-1221
  2. Deicher, Robert WH, Hurl (2004). Differentiating factors between erytheopoiesis-stimulating agents. Austria, Division of Nephrology and Dialysis, Departement of Medicine III, University of Vienna
  3. Elliott SG (2006). New molecules and formulations of recombinant human erythropoietin, In: Molineux G, Foote MA, Elliott SG (Eds), Erythropoietins and Erythropoiesis. Berlin, Birkhäuser Verlag/Switzerland Basel, p 244-245
  4. Febriyanti AP (2011). Peningkatan kadar hemoglobin paska pemberian eritropoetin pada pasien penyakit ginjal kronik-anemia dengan hemodialisis. Surabaya
  5. Ganz, Nemeth (2015). Iron homeostasis in host defence and inflammation. Nat Rev Immunol 15, 500–510
  6. Greene RJ, Harris NO, Goodyer LI (2008). Pathology and therapeutics for pharmacist. A Basic for Clinical Pharmacy Practice. 3rd Ed. London, Pharmaceutical Press, p 908-910
  7. Halstenson CE, Macres M, Kats Sa, et al (1991). Comparative pharmacokinetics and pharmacodyna-mics of epoetin alpha and epoetin beta. Clinical Pharmacology Therapy 50, 702–12
  8. Kasiske BL (2012). Clinical practice guideline for the evaluation and management of chronic kidney disease on national kidney foundation kidney disease improving global outcome guideline for chronic kidney disease.
  9. KDOQI (2006). Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: Hb range. American Journal of Kidney Diseases 47, S33-S53
  10. Kruske, Anja, Uehlinger DE, Gotcha, Frank, Kotankoa, Peter, Levina NW (2008). Red blood cell lifespan, erythropoiesis and hemoglobin control. In: Ronco C, Cruz DN (eds). Hemodialysis – From Basic Research to Clinical Trials. Switzerland, Karger 161, 247-254
  11. Lydia (2011). Konsensus manajemen anemia pada penyakit ginjal kronis: Perhimpunan Nefrologi Indonesia. Jakarta.
  12. Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD (2007). The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney International. Indianapolis, Internal Society of Nephrology, p 630
  13. O‘Callaghan CA (2009). The renal system at a glance. 3rd Ed. England, John Wiley & Sons Publication, p 34-35
  14. Ostrvica E, Mesic E, Ostrvica D, Delic J, Custendil SC, Hukic F (2010). Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta. Boznia and Herzegovina, Med Arch, p 4-6
  15. Schonder KS (2008). Chronic and end-stage renal disease. In: Dipiro, J. T(Eds), Pharmacotherapy principles & practice. New York, The McGraw-Hill Companies, Inc., p 373-386
  16. Skibeli V, Nissen-Lie G, Torjesen P (2001). Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin, Blood 98, 3626
  17. Storring PL, Tiplady RJ, Gaines DRE (1998). Epoetin alpha and beta differ in their erythropoietin isoform compositions and biological properties. British Journal Haematology 100, 79-89
  18. Wilson DD (2008). Mcgraw-Hill's manual of laboratory & diagnostic tests. New York, The Mcgraw-Hill Companies, p 237